Selenium and antioxidant defenses as major mediators in the development of chronic heart failure
- PMID: 16819573
- DOI: 10.1007/s10741-006-9188-2
Selenium and antioxidant defenses as major mediators in the development of chronic heart failure
Abstract
Increased oxidative stress is involved in the pathogenesis of chronic heart failure (CHF), the common end result of most cardiac diseases. Selenium is an "essential" trace element, which means that it must be supplied by our daily diet and that its blood and tissue concentrations are extremely low. Selenium has a variety of functions. It is a key component of several functional selenoproteins required for normal health. The best known of these are the antioxidant glutathione peroxidase (GPx) enzymes, which remove hydrogen peroxide and the harmful lipid hydroperoxides generated in vivo by oxygen-derived species. GPx deficiency exacerbates endothelial dysfunction, a major contributing factor in the severity of CHF symptoms, in various conditions such as hyperhomocysteinemia. This suggests that homocysteine may be involved in the CHF associated endothelial dysfunction through a peroxide-dependent oxidative mechanism. Selenium also plays a role in the control of thyroid hormone metabolism and in protection against organic and inorganic mercury. One possible additional mechanism by which low selenium may compromise cardiovascular condition may be through the effect of selenium on the synthesis and activity of deiodinases, enzymes converting thyroxin into the biologically active triiodothyronine. Selenium and iodine actually interact in cardiovascular physiology, and further studies are needed to examine their role, in isolation and in association, in the development of CHF. Thus, selenium (through its role in selenoenzymes, thyroid hormones, and interactions with homocysteine and endothelial function) appears to be a major mediator in several pathways potentially contributing to CHF development.
Similar articles
-
Selenium and thyroid.Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):815-27. doi: 10.1016/j.beem.2009.08.002. Best Pract Res Clin Endocrinol Metab. 2009. PMID: 19942156 Review.
-
Selenium, selenoproteins and the thyroid gland: interactions in health and disease.Nat Rev Endocrinol. 2011 Oct 18;8(3):160-71. doi: 10.1038/nrendo.2011.174. Nat Rev Endocrinol. 2011. PMID: 22009156 Review.
-
Selenium supply regulates thyroid function, thyroid hormone synthesis and metabolism by altering the expression of the selenoenzymes Type I 5'-deiodinase and glutathione peroxidase.Thyroidology. 1992 Apr;4(1):17-21. Thyroidology. 1992. PMID: 1284327 Review.
-
Selenium and the thyroid.Curr Opin Endocrinol Diabetes Obes. 2013 Oct;20(5):441-8. doi: 10.1097/01.med.0000433066.24541.88. Curr Opin Endocrinol Diabetes Obes. 2013. PMID: 23974773 Review.
-
Selenium deficiency, thyroid hormone metabolism, and thyroid hormone deiodinases.Am J Clin Nutr. 1993 Feb;57(2 Suppl):236S-239S. doi: 10.1093/ajcn/57.2.236S. Am J Clin Nutr. 1993. PMID: 8427195 Review.
Cited by
-
Selenium inhibits high glucose-induced cyclooxygenase-2 and P-selectin expression in vascular endothelial cells.Mol Biol Rep. 2011 Apr;38(4):2301-6. doi: 10.1007/s11033-010-0362-1. Epub 2010 Nov 5. Mol Biol Rep. 2011. PMID: 21052844
-
Heart-Specific Knockout of the Mitochondrial Thioredoxin Reductase (Txnrd2) Induces Metabolic and Contractile Dysfunction in the Aging Myocardium.J Am Heart Assoc. 2015 Jul 21;4(7):e002153. doi: 10.1161/JAHA.115.002153. J Am Heart Assoc. 2015. PMID: 26199228 Free PMC article.
-
Selenistasis: epistatic effects of selenium on cardiovascular phenotype.Nutrients. 2013 Jan 31;5(2):340-58. doi: 10.3390/nu5020340. Nutrients. 2013. PMID: 23434902 Free PMC article. Review.
-
A Comparison of Selenium Concentrations between Congestive Heart Failure Patients and Healthy Volunteers.J Tehran Heart Cent. 2012 Spring;7(2):53-7. Epub 2012 May 31. J Tehran Heart Cent. 2012. PMID: 23074638 Free PMC article.
-
Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults.Rev Endocr Metab Disord. 2022 Jun;23(3):463-483. doi: 10.1007/s11154-021-09691-9. Epub 2021 Oct 20. Rev Endocr Metab Disord. 2022. PMID: 34671932 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical